Phase II trial of recombinant interferon-α2b in patients with advanced intractable multidrug-resistant pulmonary tuberculosis: Long-term follow-up

International Journal of Tuberculosis and Lung Disease

Volumn 3, Issue 3, 1999, Pages 214-218

  Palmero, Domingo J ^a,d   Eiguchi, K ^b   Rendo, P ^c   Castro Zorrilla, L ^a   Abbate, E ^a   Gonzalez Montaner L J ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b UNIVERSIDAD DEL SALVADOR   (Argentina)

^c Bio Sidus   (Argentina)

^d NONE   (Argentina)

Author keywords

IFN alpha; MDR TB; Treatment

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ISONIAZID; KANAMYCIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RECOMBINANT ALPHA2B INTERFERON; RIFAMPICIN; SPARFLOXACIN; STREPTOMYCIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOTHERAPY; LUNG TUBERCULOSIS; MALE; MYCOBACTERIUM TUBERCULOSIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SPUTUM CULTURE;

ADULT; CHRONIC DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 0033067896     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Abbate E, Dambrosi A, Di Lonardo M, Gonzalez Montaner I. J. Multiple drug resistant pulmonary tuberculosis. Fourteen years experience in Buenos Aires (summary). Argentina. Tubercle Lung Dis 1994; 75(Suppl): 34.
2. González Montaner L J, Palmero D, Alberti F, Ambroggi M, González Montaner P J, Abbate E. Nosocomial outbreak of multidrug-resistant tuberculosis among AIDS patients in Buenos Aires, Argentina. XI International Conference on AIDS, Vancouver, Canada 1996, Abstracts Volume 2: 24 (Abstract We.B.304).
3. Iseman M D. Treatment of multidrug-resistant tuberculosis. N Engl J Med 1993; 329: 784-791.
4. Snider D E, Cauthen G M, Farer L S, et al. Drug-resistant tuberculosis (letter). Am Rev Respir Dis 1991; 144: 732.
5. Center for Disease Control. Nosocomial transmission of multidrug-resistant tuberculosis to health care workers and HIV-infected patients in an urban hospital - Florida. MMWR 1990; 39: 718-722.
6. Fischl M A, Uttamchandani R B, Daikos G L, et al. An outbreak of tuberculosis caused by multidrug-resistant tubercle bacilli among patients with HIV infection. Ann Intern Med 1992; 117: 177-183.
7. Yoneda T, Narita N, Mikami R, Shira F. Clinical and immunological study on chronic, intractable pulmonary tuberculosis. An immune spectrum in pulmonary tuberculosis. Kekkaku 1988; 62: 11-12.
8. Schluger W N, Rom W N. The host immune response to tuberculosis. Am J Respir Crit Care Med 1998; 157: 679-691.
9. Palma Beltrán O, Eiguchi K, Kantor I N, Eisele E, Barrera L, Perez Escalante L. Immunological evaluation of patients with pulmonary tuberculosis in Buenos Aires (abstract). Am Rev Respir Dis 1990; 141: A 799.
10. Sampaio E P, Moreira A L, Sarno F N, Malta A M, Kaplan G. Prolonged treatment with recombinant interferon gamma induces Erythema nodosum leprosum in lepromatous leprosy patients. J Exp Med 1992; 175: 1729-1737.
11. Holland S M, Eisenstein E M, Kuhns D B, et al. Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma. N Engl J Med 1994; 330: 1348-1355.
12. Zaragoulidis K, Christaki P, Papazoglou A, Vamvalis C H. Synergistic activity of rIFN α2α in combination with 'classic' antituberculosis chemotherapy in a patient with advanced resistant tuberculosis and diabetes mellitus (case report). European Congress of Respiratory Diseases, Florence, 1993, (Abstract) p 276.
13. Miller A B, Hoogstraten B, Straquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
14. Gónzalez-Amaro R, Alcocer-Varela J, Martínez-Cordero E, Alarcón Segovia D. Natural killer cell-mediated activity in mixed connective tissue disease and its response to induction by interleukin-2. J Clin Immunol 1984; 4: 273-279.
15. Zoon K C, Bekisz J, Miller D. Human interferon alpha family: protein structure and function. In: Baron S, Coppenhaver D H, Dianzani F, et al., eds. Interferon: principles and medical applications. Galveston, TX; The University of Texas Medical Branch, 1992: 33-45.
16. Pestka S, Langer J A, Zoon K C, Samuel C E. Interferons and their actions. Ann Rev Biochem 1987; 56: 727-777.
17. Semenzato G, Pizzolo G, Agostini P C, et al. α-interferon activates the natural killer system in patients with hairy cell leukemia. Blood 1986; 68: 293-296.
18. Nistico P, Tecce R, Giacomini P, et al. Effect of recombinant human leukocyte, fibroblast, and immune interferons on expression of class I and II major histocompatibility complex and invariant chain in early passage human melanoma cells. Cancer Res 1990; 50: 7422-7429.
19. Kurzrick R, Talpaz M, Gutterman J U. Interferons α, β and γ: basic principles and preclinical studies. In: De Vita V T, Helman S, Rosemberg A, eds. Biological Therapy of Cancer. New York, NY; J B Lippincott Co, 1991: 247-275.
20. Nathan C F, Murray H W, Wiebe M E, et al. Identification of interferon gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med 1983; 158: 670-689.
21. Flesch I, Kaufmann S H. Mycobacterial growth inhibition by interferon-gamma-activated bone marrow macrophages and differential susceptibility among strains of Mycobacterium tuberculosis. J Immunol 1987; 138:4408-4413.
22. Dalton D K, Pitts-Meek S, Keshav S, et al. Multiple defects of immune cell function in mice with disrupted interferon-γ genes. Science 1993; 259: 1739-1742.
23. Stenger S, Mazzaccaro R J, Uyemura K, et al. Differential effects of cytolytic T cell subsets on intracellular infection. Science 1997; 276: 1684-1687.
24. Tan J S, Canaday D H, Boom W H, Balaji K N, Schwander S K, Rich K A. Human alveolar T lymphocyte responses to Mycobacterium tuberculosis antigens: role for CD4+ and CD8+ cytotoxic T cells and relative resistance of alveolar macrophages to lysis. J Immunol 1997; 159: 290-297.
25. Recht M, Borden E C, Knight K Jr. A human 15-kDa IFN-induced protein induces the secretion of INF-gamma. J Immunol 1991; 147: 2617-2623.
26. Brinkmann V, Geiger T, Alkan S, Heusser C H. Interferon-α increases the frequency of interferonγ-producing human CD4+ T cells. J Exp Med 1993; 178: 1655-1663.
27. Sodhi A, Gong J, Silva C, Qian D, Barnes P F. Clinical correlates of interferon gamma production in patients with tuberculosis. Clin Infect Dis 1997; 25: 617-620.
28. Onwubalili J K, Scott G M, Robinson J A. Deficient immune interferon production in tuberculosis. Clin Exp Immunol 1985; 59: 405-413.
29. Tada A, Kawahara S, Tamaoki A, et al. Interferon production in peripheral blood cells of patients with pulmonary mycobacterial disease. Nippon Kyobu Sikkan Gakkai Zasshi 1995; 33: 114-119.
30. Rigby W F, Ball E D, Guyre P M, Fanger M W. The effects of recombinant DNA-derived interferons on the growth of myeloid progenitor cells. Blood 1985; 68: 858-861.
31. Sayers T J, Wiltrout T A, McCormick K, Husted C, Wiltrout R H. Antitumor effects of α-interferon and γ-interferon on a murine renal cancer (Renca) in vitro and in vivo. Cancer Res 1990; 50: 5414-5420.
32. World Health Organization Global Tuberculosis Programme. Antituberculosis drug resistance in the world. The WHO/ IUATLD Global project on antituberculosis drug resistance surveillance 1994-1997. Geneva; WHO (WHO/TB/97.229).